Objective/Hypothesis: Therapeutic agents that enhance mucociliary transport (via stimulation of transepithelial Cl À secretion) and inhibit inflammation could provide considerable advantages over conventional treatments for chronic rhinosinusitis (CRS). The objectives of the present study were to investigate whether the polyphenolic compound resveratrol promotes transepithelial Cl À transport and inhibits KC/IL-8 secretion in sinonasal epithelium. Study Design: In vitro and in vivo study. Methods: Transepithelial Cl À transport was investigated in primary murine nasal septal (MNSE) and human sinonasal epithelial (HSNE) cultures. In vivo activity was also measured using the murine nasal potential difference assay. CFTR R-domain phosphorylation and cAMP levels were examined as a test of cAMP/PKA-dependent activation. In vitro LPS-induced KC/ IL-8 secretion was quantified and compared to a panel of intranasal steroids.
INTRODUCTION
Airway surface liquid (ASL) is a critical part of the mucociliary apparatus that is modulated by the epithelial transport of ions, such as chloride (Cl À ) and sodium (Na þ ). One of the primary regulators of Cl À transport in sinonasal respiratory epithelium is the cystic fibrosis transmembrane conductance regulator (CFTR). Dysfunctional Cl À transport results in dehydrated ASL and mucus stasis as demonstrated in the global airway disease, cystic fibrosis (CF). Disrupted mucociliary clearance (MCC) places patients at risk for developing bacterial infections in the upper and lower airway leading to chronic inflammation and persistent problems with mucus transport. 1, 2 Although chronic rhinosinusitis (CRS) is pervasive in the CF population, strategies designed to improve MCC in individuals without this disease are lacking.
Enhancing transepithelial Cl À secretion in the upper airway represents a new and leading edge approach to treatment that has recently been shown to activate MCC in human subjects, 3 but has not been investigated previously in CRS. Compounds that stimulate Cl À secretion, specifically those that activate CFTR are an area of active investigation for the treatment of CF and other respiratory diseases. 4, 5 Flavonoids, a group of ubiquitous plant molecules known for their antibacterial, antiviral, anti-inflammatory, and antiallergic properties, are among the most potent activators of CFTR gating. [6] [7] [8] Our prior studies indicate that these compounds may represent an effective therapeutic approach to enhancing transepithelial Cl À secretion in sinonasal respiratory epithelium. 4, 6 Resveratrol, a natural polyphenol related to flavonoid compounds, is found in various vegetables and fruits and is abundant in grapes. 9 The molecule has well-known anti-inflammatory properties attributable to the inhibition of NF-jB, 10 which may decrease the expression of many inflammatory proteins (granulocytemacrophage colony stimulating factor [GM-CSF]), IL-8 (or the murine homologue KC), COX-2, and inducible nitric oxide synthase (iNOS). 11 Agents with an excellent safety profile that both inhibit inflammation and promote epithelial Cl À secretion could be of benefit in individuals suffering from inflammatory sinus disease. Due to the structural similarity to flavonoid compounds, we sought to determine whether resveratrol could serve as a Cl À secretagogue and anti-inflammatory agent in sinus and nasal epithelium.
METHODS
The University of Alabama at Birmingham Institutional Animal Care and Use Committee and institutional review board approval were obtained prior to initiation of the study.
Tissue Culture
Techniques for murine nasal septal epithelia (MNSE) and human sinonasal epithelia (HSNE) culture on air-liquid interfaces have been described in previous studies. 4, [12] [13] [14] [15] [16] [17] [18] All MNSE cells were obtained from C57/BL6 wild-type mice and from transgenic CFTR À/À knockout mice. Primary nasal epithelial cells were prepared and cultured according to previously established protocols 17 on collagen-coated Costar 6.5-mm-diameter permeable filter supports (Corning, Lowell, MA) submerged in culture media. HSNE was obtained from nasal epithelial tissue removed during endoscopic skull base surgery from individuals without evidence of sinusitis. Differentiation and ciliogenesis occurred in all cultures within 10 to 14 days.
Short Circuit (ISC) Measurements
Transwell inserts (Costar) were mounted in Ussing chambers in order to investigate pharmacologic manipulation of vectorial ion transport. Monolayers were continuously monitored under short circuit conditions following fluid resistance compensation using automatic voltage clamps (VCC 600; Physiologic Instruments, San Diego, CA). Batch solutions for the transwell filters were warmed to 37 C, and each solution continuously gas lifted with a 95%O 2 -5%CO 2 mixture. DMSO control solutions were tested for comparison. The I SC was assessed at one current measurement per second. By convention, a positive deflection in I SC was defined as the net movement of anions in the serosal to mucosal direction.
Nasal Potential Difference Assay
A three-step protocol was used, as described previously. 4 Animals were anesthetized with ketamine (200 mg/kg), acepromazine (0.6 mg/kg), and xylazine (30 mg/kg) by intraperitoneal injection prior to testing. First, nasal cavities of anesthetized mice (C57/BL6) were perfused sequentially with 1) Ringer's solution containing 140 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 10 mM HEPES, and amiloride 50 lM (pH 7.3); 2) amiloride þ a low-Cl À -containing solution (NMDG, 6 mM Cl À , pH 7.3); and 3) amiloride þ low-Cl À -containing solution þ hesperidin, forskolin 20 mM, or DMSO control. Because of the continuous presence of amiloride (50 lM) and the complete replacement of Na þ with a membrane-impermeant cation (140 mM NMDG in the perfusion solution), hyperpolarization in this setting is taken to reflect Cl À secretion rather than sodium absorption. Each condition was studied for 5 to 10 minutes until a stable signal was achieved. Activity of the test solution was measured from the stable baseline to the highest point of hyperpolarization. All traces were interpreted in a blinded fashion.
CFTR R-Domain Phosphorylation and cAMP Levels
Because activation of CFTR anion transport requires protein kinase A (PKA)-dependent phosphorylation of the R-D, an ELISA-based detection kit (Cayman Chemicals, Ann Arbor, MI) was used to measure stimulation of cellular cAMP by resveratrol in MNSE cultures, as previously described. 7 To confirm absence of a cAMP/PKA-dependent mechanism, polyclonal NIH-3T3 cells expressing HA-tagged R-domain were treated with resveratrol for 20 minutes, and compared to forskolin (100 nM) Â 5 minutes as a positive control and DMSO as negative control. Following lysis, equal amounts (50 lg) of total cell lysate were electrophoresed through a 12% sodium dodecyl sulfatepolyacrylamide gel (SDS-PAGE), and immunoblotted with antibody to the HA tag (Covance, Cumberland, VA). Phosphorylation of the R-domain was visualized as a 2-4 kDa shift in migration, as previously described. 7 KC and IL-8 ELISA LPS (derived from Escherichia coli, Sigma, St. Louis, MO) was dissolved in stock solutions of commonly prescribed topical steroids for allergic rhinitis (budesonide, triamcinolone acetonide, fluticasone propionate, and ciclesonide) in PBS solution at a final concentration of 100 ng/mL. Solutions were vortexed immediately prior to incubation to ensure adequate dissolution and homogenous application of steroids to each well. The positive and negative controls were LPS and DMSO (resveratrol vehicle), respectively. Steroid concentrations were derived from the total micrograms per volume of spray as provided on product prescribing information (budesonide 32 lL/spray, triamcinolone acetonide 55lL/spray, fluticasone propionate 67lL/spray, ciclesonide 50 lL/spray). A 4-hour incubation time point was chosen based on initial experiments with MNSE. All cell plates were maintained at 37 C and 5% CO 2 for 4 hours. Basal media from MNSE were used to measure mouse CXCL1/ KC (functional homolog of human IL-8) ELISAs (R&D Systems, Minneapolis, MN). Media from incubated HSNE was run on a human CXCL8/IL-8 ELISA (R&D Systems). Absorbance analyses for all ELISAs were performed on a Bio-Rad (Hercules, CA) microplate absorbance spectrophotometer. Linear regression analysis of standard solutions to calculate sample concentrations was run on Microplate Manager 5.2.1 (BioRad) software. Cilia beat frequency (CBF) and cellular integrity were analyzed to ensure the health of the cells before and after incubations.
Statistical Analysis
Statistical analyses were performed using two-tailed unpaired t-tests, paired t-tests, and analysis of variance as indicated.
RESULTS

Resveratrol is a Robust CFTR-Dependent Cl
2 Secretagogue CFTR-mediated anion transport (change in shortcircuit current, DI SC ) was analyzed using MNSE cultures in Ussing chambers (Fig. 1A) . Resveratrol activated CFTR dependent Cl À conductance in a dose dependent fashion up to 500 lM, but demonstrated inhibitory effects on total CFTR activation with posttreatment forskolin (100 nM) at concentrations greater than 100 lM (Fig. 1B) . Thus, 100 lM resveratrol (DI SC , 13.51 6 0.77 vs. 4.4 6 0.66 [control]; P < .05) was considered the optimal dose for the remainder of the studies. Although total stimulated DI SC was maximal at 100 lM (27.35 6 2.11), there was no significant difference when compared to forskolin alone (23 (Fig. 1C) . Although inhibition of total achievable I SC (resveratrol þ forskolin)was noted at concentrations up to 10 mM resveratrol, stimulation of transepithelial Cl À secretion was still present at all concentrations (data not shown). CFTR À/À knockout MNSE were used to confirm that resveratrol-stimulated DI SC is mediated through a CFTR-dependent mechanism (Fig. 1D) . Following application of amiloride (used to block sodium channels and support DI SC attributable to Cl À transport), resveratrol (100 lM) resulted in no measurable transepithelial conductance and, thus, no contribution from alternative Cl À transport pathways (i.e., calcium-activated Cl À channels) was implicated (see also below).
Resveratrol (100 lM) Increases Transepithelial Cl 2 Transport in HSNE
Once an optimal dose was determined in MNSE, confirmation in primary HSNE cultures was performed using the 100 lM concentration (Fig. 2A) were also significantly increased when compared to forskolin alone (Fig. 2B) . 
Resveratrol Activates CFTR-Dependent Cl
2
Conductance Across In Vivo Murine Nasal Epithelium
We next examined the effects of resveratrol on Cl À transport in vivo via standardized murine NPD measurements. Mice demonstrated significant hyperpolarization following perfusion with resveratrol (100 lM) in the presence of amiloride (100 lM) and a Cl À secretory gradient (À4 6 1.87 mV) compared with continued depolarization seen in mice perfused with vehicle and otherwise identical conditions [À0.93 6 1.69 mV, P < .01). Although increased when compared to forskolin (À1.65 6 1.78 mV), this was not statistically significant (Fig. 3) .
Resveratrol Activates CFTR in the Absence of R-Domain Phosphorylation
PKA/cAMP-dependent phosphorylation of the CFTR R-Domain (R-D) is a crucial step in channel activation, but it has been previously demonstrated that flavonoid compounds, including genistein 19 and hesperidin, 6 activate CFTR through a mechanism independent of PKA/ cAMP-dependent phosphorylation of the R-D. To examine the mechanistic basis of CFTR activation by resveratrol, we measured the effects of resveratrol on cAMP levels and R-D phosphorylation. As opposed to the cAMP agonist forskolin, resveratrol had no detectable effect on the phosphorylation-dependent mobility shift of recombinant CFTR R-D and did not confer a significant elevation in cAMP (Fig. 4) .
Resveratrol Inhibition of KC/IL-8 Secretion Compares Favorably to Topical Intranasal Steroids
Resveratrol significantly suppressed LPS-induced KC production (181 6 39pg/mL [ (Fig. 5A) . Resveratrol also abrogated LPS-induced KC secretion when compared to selected topical steroids applied at pharmacologic concentrations. KC was significantly decreased (P < .001) with application of 100, 200, and 500 lM concentrations of resveratrol when compared to budesonide (742 6 428 pg/mL), triamcinolone acetonide (561 6 124 pg/mL), and ciclesonide (765 6 139 pg/mL). Resveratrol had similar activity on KC inhibition compared to fluticasone propionate (94 6 16 pg/mL). Strong anti- inflammatory activity was also demonstrated in HSNE cultures as judged by release of the KC homolog IL-8 (Fig. 5B) . Resveratrol (100lM) significantly suppressed LPS-induced IL-8 production (975 6 244 pg/mL [100 lM] versus 1,825 6 144 pg/mL [LPS control]; P < .001) and was not significantly different from fluticasone proprionate (785 6 277). Because DMSO also significantly stimulates IL-8 secretion (958 6 216 pg/mL vs. 504 6 284 pg/mL; PBS; P < .05), the corresponding amount of DMSO required for 100 lM resveratrol was used for each condition. Resveratrol without LPS (757 6 42) did not suppress IL-8 secretion below constitutive levels. Fluticasone without LPS or DMSO decreased IL-8 constitutive expression (349 6 25) but was not significantly different than PBS controls.
DISCUSSION
Flavonoids are a group of small molecules structurally derived from plant-based compounds of the common flavone (2-phenyl-c-benzopyrone). 5 Numerous flavonoid compounds have garnered attention over the last decade based upon a variety of health benefits and favorable biological activities. Although resveratrol lacks the central ring of the common three ring flavone backbone, it is otherwise structurally similar to flavonoids as it is a polyphenolic molecule. Resveratrol is found in the skins of red fruits, trees, some flowering plants, and peanuts. 9, 20 Prior studies have demonstrated antioxidative, antiproliferative, anti-inflammatory, cardioprotective, anticancer, and even chemopreventative properties. 20, 21 Although not an inhibitor of inducible gene transcription directly, 20 the compound appears to play a role in numerous cellular pathways including the inhibition of the transcription factor NF-jB and activator protein-1(AP-1). 10 The present studies revealed that resveratrol is a robust activator of CFTR-dependent transepithelial Cl À transport in vitro (murine and human primary cell culture models of sinonasal epithelium) and in vivo (murine NPD assay). CFTR is the major Cl À channel in the apical membranes of respiratory epithelia and is responsible for modulating ASL via salt and water secretion and absorption. 4 Dysfunctional Cl À transport may be genetic (i.e., cystic fibrosis) or acquired (cigarette smoke exposure, high altitude/hypoxemia, inflammation, and infectious agents). 2, 6 The loss of CFTR causes dehydration of the ASL and interference with MCC, resulting in widespread respiratory disease. Novel Cl À secretagogues, Resveratrol has superior anti-inflammatory activity compared to intranasal steroids. (A) Lipopolysaccharide (LPS)-stimulated KC production was inhibited in a dose-dependent fashion and strongly decreased at doses greater than or equal to 100 lM in murine nasal septal epithelium (n ! 5 per condition) (P < .0001).
Resveratrol equal to or greater than 100 lM suppressed KC more strongly than three major intranasal steroids (budesonide, triamcinolone acetonide, and ciclesonide) (P < .0001). (B) LPS-stimulated IL-8 production was significantly abrogated (n ! 3 per condition, P < .001) in human sinonasal epithelial cultures exposed to resveratrol (100 lM) and was comparable to fluticasone. DMSO significantly stimulates IL-8 secretion by itself (P < .05) compared to phosphate-buffered saline (PBS).
such as VX-770, have shown considerable clinical promise in CF, and have generated a great deal of recent excitement. 22, 23 Because molecules such as these activate Cl À secretion in the upper as well as lower airways, the agents may benefit subjects with CRS and impaired nasal mucus clearance. Certain flavonoids [24] [25] [26] and related compounds, such as resveratrol in the present investigations, have demonstrated robust activation of CFTR-mediated anion transport and, thus, represent an excellent prototypic resource for investigating the mechanisms underlying CRS and as part of therapeutic development for acquired defects in CFTR.
Resveratrol activation of transepithelial Cl À secretion was robustly inhibited by the specific CFTR blocker INH-172, indicating that activation of transepithelial Cl À secretion in nasal airway epithelium is largely dependent upon CFTR. When resveratrol was administered in CFTR À/À MNSE in the presence of amiloride, no measurable DI SC was detected further establishing reliance on apical CFTR for activation of ion transport. Although stimulation of CFTR is dependent upon the phosphorylation of the R domain by the cAMP/PKA dependent pathway, our results provide evidence that resveratrol promotes CFTR activation in a manner distinct from that produced by classic PKA dependent stimuli. Resveratrol did not produce elevated cAMP levels and no R-domain phosphorylation was detected following treatment. Previous work from our group has shown that CFTR channel activation by hesperidin, 6 quercetin, 7 and the bioflavonoid mixture Sinupret V R 4 can be blocked by inhibiting PKA. This implies that CFTR requires some level of PKA activity (and thus PKA-dependent R-domain phosphorylation) for compounds in this class to mediate Cl À transport in intact cells from sinonasal epithelium. Thus, we speculate that resveratrol increases channel opening in CFTR that has already entered the phosphorylated state-a mechanism currently under investigation in our laboratory by membrane patch analysis of CFTR single channels and macropatches pre and post-PKA administration.
Interleukin-8 (IL-8) gene expression levels have been shown to correlate with disease severity in CRS. 27 In the murine model, KC has been suggested to be a functional homolog of IL-8, as it is known to mediate neutrophilic infiltration in association with acute and chronic airway inflammation. 28 Resveratrol has been shown to inhibit IL-8 and GM-CSF release by alveolar macrophages from patients with chronic obstructive pulmonary disease (COPD) under conditions where steroids were largely ineffective. 20, 29 The current study demonstrated that resveratrol significantly suppressed LPSinduced KC production in a dose-dependent fashion in MNSE and inhibited IL-8 production in HSNE. In addition, the anti-inflammatory activity of resveratrol with regard to KC suppression was superior to several commonly prescribed intranasal steroids (budesonide, triamcinolone acetonide, and ciclesonide) and similar to fluticasone propionate (in MNSE and HSNE) after 4 hours of application. This data, in combination with evidence indicating strong topical activation of Cl À transport in vivo, suggests that intranasal resveratrol could play an important role in drug discovery efforts aiming to activate or potentiate CFTR in respiratory diseases. Although topical administration of resveratrol has been investigated as an antioxidant supplement in sunscreen, 30 to our knowledge, this is the first study demonstrating the applicability of an intranasal topical formulation of the compound as a possible therapy in chronic rhinosinusitis.
CONCLUSION
These in vitro and in vivo findings indicate resveratrol is both a potent Cl À secretagogue and antiinflammatory agent-the combination of such properties make resveratrol a unique and promising topical therapeutic agent for inflammatory sinus and nasal disease. Future human clinical trials investigating resveratrol preparations in CRS and other airway diseases are warranted.
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